For a long time, eosinophils were regarded as the central effector cells of asthma and were interpreted in the classical model as a direct damaging agent of the epithelium, as an amplifier of bronchial hyperresponsiveness and as the main driver of type 2-mediated airway inflammation. Scientific developments over the past two decades have differentiated, expanded and in some cases questioned this picture. Are eosinophils in fact primary culprits – or merely markers of more complex immunological patterns? A new Lancet publication sheds some light on this.
Autoren
- Tanja Schliebe
Publikation
- Asthma/COPD-Special
Related Topics
You May Also Like
- Study report
Asthma exacerbation risk in patients with a psychological comorbidity
- Neuropathies - CIDP
Differentiate chronic inflammatory demyelinating polyneuropathy (CIDP)
- Treatment of type 2 diabetes: paradigm shift continues
Cardiorenal organ protection is increasingly coming to the fore
- Semaglutide and tirzepatide in HFpEF and T2D/obesity
Prospect of improved cardiovascular prognosis
- Case report: alveolar sarcoidosis
Acute hypoxemic respiratory failure as initial manifestation
- "Swiss Health Care Atlas"
Supply situation in Switzerland: Update
- Lung cancer
Multidisciplinary teams in oncology
- Adrenogenital syndrome